{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:30:38Z","timestamp":1794047438609,"version":"4.8.0"},"reference-count":39,"publisher":"Ferrata Storti Foundation (Haematologica)","issue":"1","license":[{"start":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T00:00:00Z","timestamp":1687392000000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["haematol"],"abstract":"<jats:p>Measurable residual disease (MRD) is a powerful predictor of outcome in acute myeloid leukemia. In the early phases of treatment, MRD refines initial disease risk stratification and is used for the allocation to allogeneic transplant. Despite its well-established role, a relatively high fraction of patients eventually relapses albeit achieving MRDneg status. The aim of this work was to assess specifically the influence of baseline features and treatment intensity on the predictive value of an MRDneg status, particularly focusing on MRD2, measured after two consecutive chemotherapy cycles. Among baseline features, younger MRD2neg patients (&lt;55 years) had a significantly longer disease-free survival (median not reached) compared to their older counterparts (median 25.0 months, P=0.013, hazard ratio=2.08). Treatment intensity, specifically the delivery of a high dose of cytarabine in induction or first consolidation, apparently had a pejorative effect on the outcome of MRD2neg patients compared to standard dose (P=0.048, hazard ratio=1.80), a finding also confirmed by the analysis of data extracted from the literature. The combination of age and treatment intensity allowed us to identify categories of patients, among those who reached a MRD2neg status, characterized by significantly different disease-free survival rate. Our data showed that variables such as age and intensity of treatment administered can influence the predictive value of MRD in patients with acute myeloid leukemia. In addition to underscoring the need for further improvement of MRD analysis, these findings call for a reasoned application of MRD data, as currently available, to modulate consolidation therapy on adequately estimated relapse rates.<\/jats:p>","DOI":"10.3324\/haematol.2023.283196","type":"journal-article","created":{"date-parts":[[2023,6,22]],"date-time":"2023-06-22T03:46:06Z","timestamp":1687405566000},"page":"60-71","source":"Crossref","is-referenced-by-count":1,"title":["Effect of age and treatment on predictive value of measurable residual disease: implications for clinical management of adult patients with acute myeloid leukemia"],"prefix":"10.3324","volume":"109","author":[{"given":"Francesco","family":"Mannelli","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matteo","family":"Piccini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sara","family":"Bencini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giacomo","family":"Gianfaldoni","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Benedetta","family":"Peruzzi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roberto","family":"Caporale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Barbara","family":"Scappini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura","family":"Fasano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elisa","family":"Quinti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gaia","family":"Ciolli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Pasquini","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesca","family":"Crupi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sofia","family":"Pilerci","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiana","family":"Pancani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leonardo","family":"Signori","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danilo","family":"Tarantino","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chiara","family":"Maccari","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vivian","family":"Paradiso","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Francesco","family":"Annunziato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paola","family":"Guglielmelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro M.","family":"Vannucchi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1856","published-online":{"date-parts":[[2023,6,22]]},"reference":[{"key":"55897","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Wei AH, Appelbaum FR. Diagnosis and management of AML in adults: 2022 ELN recommendations from an international expert panel. Blood. 2022; 140(12):1345-1377.","DOI":"10.1182\/blood.2022016867"},{"key":"55898","doi-asserted-by":"crossref","unstructured":"Miguel JFS, Mart\u00ednez A, Macedo A. Immunophenotyping investigation of minimal residual disease is a useful approach for predicting relapse in acute myeloid leukemia patients. Blood. 1997; 90(6):2465-2470.","DOI":"10.1182\/blood.V90.6.2465.2465_2465_2470"},{"key":"55899","doi-asserted-by":"crossref","unstructured":"Venditti A, Buccisano F, Poeta DG. Level of minimal residual disease after consolidation therapy predicts outcome in acute myeloid leukemia. Blood. 2000; 96(12):3948-3952.","DOI":"10.1182\/blood.V96.12.3948"},{"key":"55900","doi-asserted-by":"crossref","unstructured":"Terwijn M, Putten WL van, Kelder A. High prognostic impact of flow cytometric minimal residual disease detection in acute myeloid leukemia: data from the HOVON\/SAKK AML 42A study. J Clin Oncol. 2013; 31(31):3889-3897.","DOI":"10.1200\/JCO.2012.45.9628"},{"key":"55901","doi-asserted-by":"crossref","unstructured":"Ivey A, Hills RK, Simpson MA. Assessment of minimal residual disease in standard-risk AML. N Engl J Med. 2016; 374(5):422-433.","DOI":"10.1056\/NEJMoa1507471"},{"key":"55902","doi-asserted-by":"crossref","unstructured":"Short NJ, Zhou S, Fu C. Association of measurable residual disease with survival outcomes in patients with acute myeloid leukemia. JAMA Oncol. 2020; 6(12):1890-1899.","DOI":"10.1001\/jamaoncol.2020.4600"},{"key":"55903","doi-asserted-by":"crossref","unstructured":"Heuser M, Freeman SD, Ossenkoppele GJ. 2021 update measurable residual disease in acute myeloid leukemia: European LeukemiaNet Working Party Consensus Document. Blood. 2021; 138(26):2753-2767.","DOI":"10.1182\/blood.2021013626"},{"key":"55904","doi-asserted-by":"crossref","unstructured":"Buccisano F, Maurillo L, Principe MID. Minimal residual disease as a biomarker for outcome prediction and therapy optimization in acute myeloid leukemia. Expert Rev Hematol. 2018; 11(4):307-313.","DOI":"10.1080\/17474086.2018.1447378"},{"key":"55905","doi-asserted-by":"crossref","unstructured":"Freeman SD, Hills RK, Virgo P. Measurable residual disease at induction redefines partial response in acute myeloid leukemia and stratifies outcomes in patients at standard risk without NPM1 mutations. J Clin Oncol. 2018; 36(15):1486-1497.","DOI":"10.1200\/JCO.2017.76.3425"},{"key":"55906","doi-asserted-by":"crossref","unstructured":"Tettero JM, Freeman S, Buecklein V. Technical aspects of flow cytometry-based measurable residual disease quantification in acute myeloid leukemia: experience of the European LeukemiaNet MRD Working Party. Hemasphere. 2021; 6(1):e676.","DOI":"10.1097\/HS9.0000000000000676"},{"key":"55907","doi-asserted-by":"crossref","unstructured":"Zhu HH, Zhang HX, Qin ZY. MRD-directed risk stratification treatment may improve outcomes of t(8;21) AML in the first complete remission: results from the AML05 multicenter trial. Blood. 2013; 121(20):4056-4062.","DOI":"10.1182\/blood-2012-11-468348"},{"key":"55908","doi-asserted-by":"crossref","unstructured":"Venditti A, Piciocchi A, Candoni A. GIMEMA AML1310 trial of risk-adapted, MRD-directed therapy for young adults with newly diagnosed acute myeloid leukemia. Blood. 2019; 134(12):935-945.","DOI":"10.1182\/blood.2018886960"},{"key":"55909","doi-asserted-by":"crossref","unstructured":"Buccisano F, Maurillo L, Piciocchi A. Minimal residual disease negativity in elderly patients with acute myeloid leukemia may indicate different postremission strategies than in younger patients. Ann Hematol. 2015; 94(8):1319-1326.","DOI":"10.1007\/s00277-015-2364-5"},{"key":"55910","doi-asserted-by":"crossref","unstructured":"Jentzsch M, Grimm J, Bill M. Clinical value of the measurable residual disease status within the ELN2017 risk groups in AML patients undergoing allogeneic stem cell transplantation. Am J Hematol. 2021; 96(7):E237-E239.","DOI":"10.1002\/ajh.26179"},{"key":"55911","doi-asserted-by":"crossref","unstructured":"Burnett AK, Goldstone A, Hills RK. Curability of patients with acute myeloid leukemia who did not undergo transplantation in first remission. J Clin Oncol. 2013; 31(10):1293-1301.","DOI":"10.1200\/JCO.2011.40.5977"},{"key":"55912","doi-asserted-by":"crossref","unstructured":"Castaigne S, Chevret S, Archimbaud E. Randomized comparison of double induction and timed-sequential induction to a \u201c3 + 7\u201d induction in adults with AML: long-term analysis of the Acute Leukemia French Association (ALFA) 9000 study. Blood. 2004; 104(8):2467-2474.","DOI":"10.1182\/blood-2003-10-3561"},{"key":"55913","doi-asserted-by":"crossref","unstructured":"Bassan R, Intermesoli T, Masciulli A. Randomized trial comparing standard vs sequential high-dose chemotherapy for inducing early CR in adult AML. Blood Adv. 2019; 3(7):1103-1117.","DOI":"10.1182\/bloodadvances.2018026625"},{"key":"55914","doi-asserted-by":"crossref","unstructured":"Mannelli F, Bencini S, Piccini M. Multilineage dysplasia as assessed by immunophenotype in acute myeloid leukemia: a prognostic tool in a genetically undefined category. Cancers. 2020; 12(11):3196.","DOI":"10.3390\/cancers12113196"},{"key":"55915","doi-asserted-by":"crossref","unstructured":"Mannelli F, Gianfaldoni G, Bencini S. Early peripheral blast cell clearance predicts minimal residual disease status and refines disease prognosis in acute myeloid leukemia. Am J Hematol. 2020; 95(11):1304-1313.","DOI":"10.1002\/ajh.25942"},{"key":"55916","doi-asserted-by":"crossref","unstructured":"Schuurhuis GJ, Heuser M, Freeman S. Minimal\/measurable residual disease in AML: a consensus document from the European LeukemiaNet MRD Working Party. Blood. 2018; 131(12):1275-1291.","DOI":"10.1182\/blood-2017-09-801498"},{"key":"55917","doi-asserted-by":"crossref","unstructured":"Gabert J, Beillard E, van der Velden VHJ. Standardization and quality control studies of \u2018real-time\u2019 quantitative reverse transcriptase polymerase chain reaction of fusion gene transcripts for residual disease detection in leukemia \u2013 a Europe Against Cancer program. Leukemia. 2003; 17(12):2318-2357.","DOI":"10.1038\/sj.leu.2403135"},{"key":"55918","doi-asserted-by":"crossref","unstructured":"Grimwade D, Hills RK, Moorman AV. Refinement of cytogenetic classification in acute myeloid leukemia: determination of prognostic significance of rare recurring chromosomal abnormalities among 5876 younger adult patients treated in the United Kingdom Medical Research Council trials. Blood. 2010; 116(3):354-365.","DOI":"10.1182\/blood-2009-11-254441"},{"key":"55919","doi-asserted-by":"crossref","unstructured":"D\u00f6hner H, Estey E, Grimwade D. Diagnosis and management of AML in adults: 2017 ELN recommendations from an international expert panel. Blood. 2017; 129(4):424-447.","DOI":"10.1182\/blood-2016-08-733196"},{"key":"55920","doi-asserted-by":"crossref","unstructured":"Guyot P, Ades A, Ouwens MJ, Welton NJ. Enhanced secondary analysis of survival data: reconstructing the data from published Kaplan-Meier survival curves. BMC Med Res Methodol. 2012; 12(1):9.","DOI":"10.1186\/1471-2288-12-9"},{"key":"55921","doi-asserted-by":"crossref","unstructured":"Balsat M, Renneville A, Thomas X. Postinduction minimal residual disease predicts outcome and benefit from allogeneic stem cell transplantation in acute myeloid leukemia with NPM1 mutation: a study by the Acute Leukemia French Association group. J Clin Oncol. 2016; 35(2):185-193.","DOI":"10.1200\/JCO.2016.67.1875"},{"key":"55922","doi-asserted-by":"crossref","unstructured":"Buccisano F, Maurillo L, Piciocchi A. Pre-transplant persistence of minimal residual disease does not contraindicate allogeneic stem cell transplantation for adult patients with acute myeloid leukemia. Bone Marrow Transpl. 2017; 52(3):473-475.","DOI":"10.1038\/bmt.2016.308"},{"key":"55923","doi-asserted-by":"crossref","unstructured":"Paiva B, Vidriales M-B, Sempere A. Impact of measurable residual disease by decentralized flow cytometry: a PETHEMA real-world study in 1076 patients with acute myeloid leukemia. Leukemia. 2021; 35(8):2358-2370.","DOI":"10.1038\/s41375-021-01126-3"},{"key":"55924","doi-asserted-by":"crossref","unstructured":"Pastore F, Levine RL. Next-generation sequencing and detection of minimal residual disease in acute myeloid leukemia: ready for clinical practice?. JAMA. 2015; 314(8):778-780.","DOI":"10.1001\/jama.2015.9452"},{"key":"55925","doi-asserted-by":"crossref","unstructured":"Klco JM, Miller CA, Griffith M. Association between mutation clearance after induction therapy and outcomes in acute myeloid leukemia. JAMA. 2015; 314(8):811-822.","DOI":"10.1001\/jama.2015.9643"},{"key":"55926","doi-asserted-by":"crossref","unstructured":"Jongen-Lavrencic M, Grob T, Hanekamp D. Molecular minimal residual disease in acute myeloid leukemia. N Engl J Med. 2018; 378(13):1189-1199.","DOI":"10.1056\/NEJMoa1716863"},{"key":"55927","doi-asserted-by":"crossref","unstructured":"Buccisano F, Palmieri R, Piciocchi A. Clinical relevance of an objective flow cytometry approach based on limit of detection and limit of quantification for measurable residual disease assessment in acute myeloid leukemia. A post-hoc analysis of the GIMEMA AML1310 trial. Haematologica. 2022; 107(12):2823-2833.","DOI":"10.3324\/haematol.2021.279777"},{"key":"55928","doi-asserted-by":"crossref","unstructured":"Li S-Q, Xu L-P, Wang Y. An LSC-based MRD assay to complement the traditional MFC method for prediction of AML relapse: a prospective study. Blood. 2022; 140(5):516-520.","DOI":"10.1182\/blood.2021014604"},{"key":"55929","doi-asserted-by":"crossref","unstructured":"Zeijlemaker W, Kelder A, Oussoren-Brockhoff YJM. A simple one-tube assay for immunophenotypical quantification of leukemic stem cells in acute myeloid leukemia. Leukemia. 2016; 30(2):439-446.","DOI":"10.1038\/leu.2015.252"},{"key":"55930","doi-asserted-by":"crossref","unstructured":"Breems DA, Putten WLJV, Huijgens PC. Prognostic index for adult patients with acute myeloid leukemia in first relapse. J Clin Oncol. 2005; 23(9):1969-1978.","DOI":"10.1200\/JCO.2005.06.027"},{"key":"55931","doi-asserted-by":"crossref","unstructured":"Maurillo L, Buccisano F, Principe M. Toward optimization of postremission therapy for residual disease\u2013positive patients with acute myeloid leukemia. J Clin Oncol. 2008; 26(30):4944-4951.","DOI":"10.1200\/JCO.2007.15.9814"},{"key":"55932","doi-asserted-by":"crossref","unstructured":"Maurillo L, Buccisano F, Piciocchi A. Minimal residual disease as biomarker for optimal biologic dosing of ARA-C in patients with acute myeloid leukemia. Am J Hematol. 2015; 90(2):125-131.","DOI":"10.1002\/ajh.23893"},{"key":"55933","doi-asserted-by":"crossref","unstructured":"Cornelissen JJ, Blaise D. Hematopoietic stem cell transplantation for patients with AML in first complete remission. Blood. 2016; 127(1):62-70.","DOI":"10.1182\/blood-2015-07-604546"},{"key":"55934","doi-asserted-by":"crossref","unstructured":"Walter RB, Gooley TA, Wood BL. Impact of pretransplantation minimal residual disease, as detected by multiparametric flow cytometry, on outcome of myeloablative hematopoietic cell transplantation for acute myeloid leukemia. J Clin Oncol. 2011; 29(9):1190-1197.","DOI":"10.1200\/JCO.2010.31.8121"},{"key":"55935","doi-asserted-by":"crossref","unstructured":"Hourigan CS, Dillon LW, Gui G. Impact of conditioning intensity of allogeneic transplantation for acute myeloid leukemia with genomic evidence of residual disease. J Clin Oncol. 2019; 38(12):1273-1283.","DOI":"10.1200\/JCO.19.03011"}],"container-title":["Haematologica"],"original-title":[],"link":[{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283196\/75715","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/haematol.2023.283196\/76416","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/haematologica.org\/article\/download\/11131\/75715","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,11,7]],"date-time":"2026-11-07T10:04:16Z","timestamp":1794045856000},"score":1,"resource":{"primary":{"URL":"https:\/\/haematologica.org\/article\/view\/haematol.2023.283196"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6,22]]},"references-count":39,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,1,1]]}},"URL":"https:\/\/doi.org\/10.3324\/haematol.2023.283196","relation":{},"ISSN":["1592-8721","0390-6078"],"issn-type":[{"value":"1592-8721","type":"electronic"},{"value":"0390-6078","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6,22]]}}}